《中国康复理论与实践》

《中国康复理论与实践》 ›› 2007, Vol. 13 ›› Issue (06): 539-541.

• 临床研究 • 上一篇    下一篇

托卡朋添加治疗帕金森病疗效观察

张小英1; 周筠1; 管小亭1; 王拥军1; 程焱2; 王景华2; 董可辉1; 宋新杰1   

  1. 1.首都医科大学附属北京天坛医院神经内科,北京市 100050;2.天津医科大学总医院神经内科,天津市 300052
  • 收稿日期:2007-04-09 出版日期:2007-06-01 发布日期:2007-06-01

Effect of Tolcapone Added in Treatment on Parkinson's Disease

ZHANG Xiao-ying, ZHOU Yun, GUAN Xiao-ting, et al   

  1. The Department of Neurology, Tian Tan Hospital Affiliated to Capital Medical University, Beijing 100050, China
  • Received:2007-04-09 Published:2007-06-01 Online:2007-06-01

PDF (PC)

被引次数

15

摘要： 目的观察儿茶酚-氧位-甲基转移酶抑制剂(COMTI)托卡朋提高已服用复方左旋多巴的帕金森病(PD)患者的疗效、改善运动波动的情况及药物的安全性。方法50例PD患者分为试验组和对照组,每组25例,试验组应用托卡朋,每次100mg,每日3次;对照组应用安慰剂,方法相同。用药后每个月进行肝功的检查,具有运动波动的患者通过患者日记记录时间变化;观察期6个月。结果治疗后第1、2个月的统一帕金森病评定量表(UPDRS)评分试验组与对照组的差异无显著性意义(P>0.05);第3个月至第6个月的UPDRS评分差异有显著性意义(P<0.05～0.01);试验组治疗后的UPDRS评分与治疗前比较,差异有非常显著性意义(P<0.01～0.001);试验组治疗后第1、第2个月的改良Honhe-Yahr分级与治疗前比较差异无显著性意义(P>0.05),治疗后第3个月至第6个月与治疗前的差异有显著性意义(P<0.05);治疗后,试验组患者的运动波动有明显改善(P<0.01);试验组患者服用托卡朋后出现口干、恶心呕吐及便秘各3例,乏力、失眠、腹泻各2例,肌肉酸痛、腹胀、多汗、烦躁各1例,均未影响服药;服药期间,患者肝功能检测结果无明显改变。结论托卡朋可提高已服用复方左旋多巴PD患者的疗效,改善运动波动,且使用安全。

关键词: 帕金森病, 左旋多巴, 托卡朋

Abstract: Objective To observe the effect of catechol-O-methyltransferase inhibitor (COMTI) tolcapone on levodopa-treated patients with Parkinson's disease (PD) and on the motor function fluctuation, and safety taking this drug.Methods50 PD patients treated with levodopa were divided into the trial group and control group with 25 cases in each group. The patients in the trial group were given tolcapone 100 mg three times per day. The cases in the control group were given placebo with the same dose. The hepatic function of the patients was examined every month after administration. The time variety of patients' motor function fluctuation was recorded by the diary. The time of clinical observation was 6 months.ResultsThe UPDRS scores of the trial group in the first and second months after taking tolcapone were not significantly different from that of the control group ( P>0.05), but scores of the third to sixth months were significantly different from that of the control group ( P<0.05～0.01). There was a significant difference between UPDRS scores of the trial group before and after treatment ( P<0.01～0.001). The Honhe-Yahr scores of the trial group in the first and second months after treatment were not significantly different from that before treatment ( P>0.05), but scores of the third to sixth months were significantly different from that before treatment ( P<0.05). The motor function fluctuation of the patients in the trial group improved significantly after treatment ( P<0.05). The numbers of the cases had dry mouth, nausea and astriction were 3 respectively; those had acratia, insomnia and diarrhea were 2 respectively; those had muscular soreness, abdominal distention, hidrosis and fidget were 1 respectively. All adverse effects had a little influence to administration. The hepatic function of all patients had no significant change.ConclusionTolcapone can increase the curative effect of PD patients treated with levodopa and improve the motor function fluctuation, and is safety after taken.

Key words: Parkinson's disease, levodopa, tolcapone